Expert Review of Hematology最新文献_第9页

Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women. 镰状细胞病与不孕风险：对受影响女童和妇女的咨询和护理的影响。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1080/17474086.2024.2372320

Lydia H Pecker, Katie Cameron

{"title":"Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women.","authors":"Lydia H Pecker, Katie Cameron","doi":"10.1080/17474086.2024.2372320","DOIUrl":"10.1080/17474086.2024.2372320","url":null,"abstract":"Introduction: Sickle cell disease (SCD), its treatments and cures present infertility risks. Fertility counseling is broadly indicated for affected girls and women and fertility preservation may appeal to some. Several streams of evidence suggest that the reproductive lifespan of women with SCD is reduced. Pregnancy is associated with high miscarriage rates. There are enduring questions about the effects of highly effective hydroxyurea treatment on female fertility. Current conditioning regimens for gene therapy or hematopoietic stem cell transplant are gonadotoxic. Fertility preservation methods exist as non-experimental standards of care for girls and women. Clinicians are challenged to overcome multifactorial barriers to incorporate fertility counseling and fertility preservation care into routine SCD care.Areas covered: Here we provide a narrative review of existing evidence regarding fertility and infertility risks in girls and women with SCD and consider counseling implications of existing evidence.Expert opinion: Addressing fertility for girls and women with SCD requires engaging concerns that emerge across the lifespan, acknowledging uncertainty and identifying barriers to care, some of which may be insurmountable without public policy changes. The contemporary SCD care paradigm can offer transformative SCD treatments alongside comprehensive counselling that addresses fertility risks and fertility preservation opportunities.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"493-504"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasound-guided joint procedures in hemophilia: technique, indications and tips. 超声引导下的血友病关节手术：技术、适应症和提示。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-07-17 DOI: 10.1080/17474086.2024.2380477

Hortensia De la Corte-Rodriguez, E Carlos Rodriguez-Merchan, M Teresa Alvarez-Roman, Primitivo Gomez-Cardero, Victor Jimenez-Yuste

{"title":"Ultrasound-guided joint procedures in hemophilia: technique, indications and tips.","authors":"Hortensia De la Corte-Rodriguez, E Carlos Rodriguez-Merchan, M Teresa Alvarez-Roman, Primitivo Gomez-Cardero, Victor Jimenez-Yuste","doi":"10.1080/17474086.2024.2380477","DOIUrl":"10.1080/17474086.2024.2380477","url":null,"abstract":"Introduction: The therapeutic approach to pain in hemophilia should be multimodal. Intra-articular injections are a good option when joint lesions do not respond to hematological treatment or rehabilitation and orthopedic surgery is not yet indicated. Performing these procedures under ultrasound guidance has been shown to improve their accuracy and efficacy.Areas covered: This article provides a practical overview of the most frequently employed ultrasound-guided intra-articular procedures on the joints of people with hemophilia. The article describes the key elements for performing the technique on the elbow, knee and ankle as the most affected joints. The particularities of the most frequent indications, arthrocentesis, synoviorthesis and analgesic injections with various products are detailed.Expert opinion: Current hematological treatments have made it possible to incorporate new therapeutic tools for pain relief for people with hemophilia, including ultrasound-guided joint procedures, which offer excellent results.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"419-430"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality of life considerations in myelodysplastic syndrome: not only fatigue. 骨髓增生异常综合征的生活质量考量：不仅仅是疲劳。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-07-12 DOI: 10.1080/17474086.2024.2378035

Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, Daniela Piccioni, Carla Mazzone, Paolo de Fabritiis

引用次数: 0

Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. 以 ikaros 和 Aiolos 为靶点：回顾用于治疗多发性骨髓瘤的新型蛋白降解剂，重点关注 iberdomide 和 mezigdomide。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-07-27 DOI: 10.1080/17474086.2024.2382897

Yuxin Liu, Clifton C Mo, Monique A Hartley-Brown, Adam S Sperling, Shonali Midha, Andrew J Yee, Giada Bianchi, Catherine Piper, Alice Tattersall, Omar Nadeem, Jacob P Laubach, Paul G Richardson

{"title":"Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.","authors":"Yuxin Liu, Clifton C Mo, Monique A Hartley-Brown, Adam S Sperling, Shonali Midha, Andrew J Yee, Giada Bianchi, Catherine Piper, Alice Tattersall, Omar Nadeem, Jacob P Laubach, Paul G Richardson","doi":"10.1080/17474086.2024.2382897","DOIUrl":"10.1080/17474086.2024.2382897","url":null,"abstract":"Introduction: The treatment of multiple myeloma (MM) is evolving rapidly. Quadruplet regimens incorporating proteasome inhibitors, immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies have emerged as standard-of-care options for newly diagnosed MM, and numerous novel therapies have been approved for relapsed/refractory MM. However, there remains a need for novel options in multiple settings, including refractoriness to frontline standards of care.Areas covered: Targeting degradation of IKZF1 and IKZF3 - Ikaros and Aiolos - through modulation of cereblon, an E3 ligase substrate recruiter/receptor, is a key mechanism of action of the IMiDs and the CELMoD agents. Two CELMoD agents, iberdomide and mezigdomide, have demonstrated substantial preclinical and clinical activity in MM and have entered phase 3 investigation. Using a literature search methodology comprising searches of PubMed (unlimited time-frame) and international hematology/oncology conference abstracts (2019-2023), this paper reviews the importance of Ikaros and Aiolos in MM, the mechanism of action of the IMiDs and CELMoD agents and their relative potency for targeting Ikaros and Aiolos, and preclinical and clinical data on iberdomide and mezigdomide.Expert opinion: Emerging data suggest that iberdomide and mezigdomide have promising activity, including in IMiD-resistant settings and, pending phase 3 findings, may provide additional treatment options for patients with MM.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"445-465"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing salvage therapy for Hodgkin lymphoma: progress and future challenges. 优化霍奇金淋巴瘤的挽救疗法：进展与未来的挑战。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-06-27 DOI: 10.1080/17474086.2024.2372325

Chathuri Abeyakoon, John Kuruvilla

{"title":"Optimizing salvage therapy for Hodgkin lymphoma: progress and future challenges.","authors":"Chathuri Abeyakoon, John Kuruvilla","doi":"10.1080/17474086.2024.2372325","DOIUrl":"10.1080/17474086.2024.2372325","url":null,"abstract":"Introduction: Despite clear advancements in the management of classical Hodgkin lymphoma (cHL) over the past decade including better risk stratification, the usage of 18F-flurodeoxyglucose positron emission tomography (FDG-PET)-guided approaches and incorporation of novel agents, approximately one-third of the patients will relapse. Important themes have been recently explored in the first salvage setting including the recognition of the positive prognostic value of a negative pre-autologous stem cell transplantation (ASCT) FDG-PET response and the incorporation of novel agents such as brentuximab vedotin (BV) and immune checkpoint inhibitors (CPIs) as salvage regimens to improve patient outcomes.Areas covered: The evolving treatment paradigm in optimizing salvage therapy in relapsed refractory cHL (RR-cHL) is discussed, including a vision to the future. The methodology included a literature search on PubMed using keywords. Selected articles were screened and evaluated by the authors of this review.Expert opinion: Achieving a complete remission by FDG-PET pre-ASCT is the most important prognostic factor in obtaining disease control and subsequent cure, and therefore should be a key goal of any salvage regimen. Although data from randomized controlled trials are currently lacking, retrospective evidence demonstrate superior event free survival with CPI-based regimens compared to conventional chemotherapy or BV-based therapy.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"467-478"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia. 环磷酰胺和马抗胸腺细胞球蛋白与氟达拉滨、减量环磷酰胺和兔抗胸腺细胞球蛋白治疗获得性再生障碍性贫血患者匹配同胞捐献者异基因造血干细胞移植的方案对比。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-07-23 DOI: 10.1080/17474086.2024.2381572

Nour Ben Abdeljelil, Insaf Ben Yaiche, Rihab Ouerghi, Lamia Torjemane, Dorra Belloumi, Ines Turki, Sabrine Mekni, Rimel Yousr Kanoun, Tarek Ben Othman, Saloua Ladeb

{"title":"Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia.","authors":"Nour Ben Abdeljelil, Insaf Ben Yaiche, Rihab Ouerghi, Lamia Torjemane, Dorra Belloumi, Ines Turki, Sabrine Mekni, Rimel Yousr Kanoun, Tarek Ben Othman, Saloua Ladeb","doi":"10.1080/17474086.2024.2381572","DOIUrl":"10.1080/17474086.2024.2381572","url":null,"abstract":"Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for acquired aplastic anemia (acquired AA) in young patients. The objective of the study was to compare patient outcomes after Cyclophosphamide and horse antithymocyte globulin (Cy-hATG) versus Fludarabine-cyclophosphamide and rabbit ATG (Flu-Cy-rATG) as part of conditioning regimen in allo-HSCT for acquired AA.Research design and methods: Descriptive retrospective study conducted on patients with acquired AA who received allo-HSCT from HLA-matched sibling donors between January 2008 and August 2022 after conditioning regimen with Cy-hATG or Flu-Cy-rATG.Results: A total of 121 patients were enrolled. Cumulative incidence of graft failure was 11.2% in Cy-hATG and 5.3% Flu-Cy-rATG group. There were no significant differences between the two groups in terms of acute GVHD, chronic GVHD, and transplant related mortality. Flu-Cy-rATG group was associated with significantly higher CMV and EBV reactivation(s) compared to Cy-hATG group (p = 0.008 and 0.035, respectively). After a median follow-up of 58 months, estimated overall survival, event-free survival, and graft rejection-free survival were not statistically different between the two groups.Conclusions: In high-risk population, Flu-Cy-rATG is associated with comparable outcomes to Cy-hATG in allo-HSCT from MSD. However, it seems to be associated with significant risk of viral infections.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"527-538"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we use biomarkers to identify those at risk of acute pain from sickle cell disease? 我们能否利用生物标志物来识别镰状细胞病急性疼痛的高危人群？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-07-05 DOI: 10.1080/17474086.2024.2372322

Varsha Bhat, Vivien A Sheehan

引用次数: 0

Update on iron supplementation in patients with cancer-related anemia. 癌症相关贫血患者补铁的最新进展。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-08-01 Epub Date: 2024-07-02 DOI: 10.1080/17474086.2024.2375265

George M Rodgers

{"title":"Update on iron supplementation in patients with cancer-related anemia.","authors":"George M Rodgers","doi":"10.1080/17474086.2024.2375265","DOIUrl":"10.1080/17474086.2024.2375265","url":null,"abstract":"Introduction: Numerous clinical trials affirm the efficacy and safety of IV iron to treat cancer-related anemia (CRA). Nonetheless, evaluation and treatment of CRA remains suboptimal.Areas covered: This review summarizes CRA therapy with a focus on iron deficiency and its treatment. The literature search was conducted using the National Library of Medicine (PubMed) database from 2004 to 2024. Topics reviewed include CRA pathophysiology, laboratory diagnosis of iron deficiency, a summary of clinical trial results using IV iron to treat CRA, and safety aspects.Expert opinion: Despite overwhelming positive efficacy and safety data, IV iron remains underutilized to treat CRA. This is likely due to persistent (unfounded) concerns about IV iron safety and lack of physician awareness of newer clinical trial data. This leads to poor patient quality of life and patient exposure to anemia treatments that have greater safety risks than IV iron. Solutions to this problem include increased educational efforts and considering alternative treatment models in which other providers separately manage CRA. The recent availability of new oral iron therapy products that are effective in treating anemia of inflammation has the potential to dramatically simplify the treatment of CRA.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"505-514"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduction of ristocetin-induced platelet aggregation (RIPA) during storage despite plasma renewal: evidence for hemostatic importance of GPIbα shedding. 尽管血浆可以更新，但储存期间利斯托西汀诱导的血小板聚集（RIPA）会降低：GPIbα脱落对止血的重要性证据。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-07-01 Epub Date: 2024-06-21 DOI: 10.1080/17474086.2024.2370557

Ehteramolsadat Hosseini, Emad Taherabadi, Ali Rajabi, Mehran Ghasemzadeh

{"title":"Reduction of ristocetin-induced platelet aggregation (RIPA) during storage despite plasma renewal: evidence for hemostatic importance of GPIbα shedding.","authors":"Ehteramolsadat Hosseini, Emad Taherabadi, Ali Rajabi, Mehran Ghasemzadeh","doi":"10.1080/17474086.2024.2370557","DOIUrl":"10.1080/17474086.2024.2370557","url":null,"abstract":"Background: Platelet storage is complicated by deleterious changes, among which reduction of ristocetin-induced platelet aggregation (RIPA) has a poorly understood mechanism. The study elucidates the mechanistic roles of all the possible players in this process.Research design and methods: PRP-platelet concentrates were subjected to RIPA, collagen-induced platelet aggregation (CIPA), and flowcytometric analysis of GPIbα and PAC-1 binding from days 0 to 5 of storage. Platelet-poor plasma was subjected to colorimetric assays for glucose/LDH evaluation and automatic analyzer to examine VWF antigen and activity.Results: From day three of platelet storage, reducing CIPA but not RIPA was correlated with the reduction of both metabolic state and integrin activity. RIPA reduction was directly related to the decreased levels of total-content/expression of GPIbα, and inversely related to its shedding levels during storage. Re-suspension of 5-day stored platelet in fresh plasma compensated CIPA, but not RIPA. VWF concentration and its activity did not change during storage while they had no correlation with RIPA.Conclusions: This study identified the irreversible loss of platelet GPIbα, but not VWF status, as the primary cause of the storage-dependent decrease of RIPA. Unlike CIPA, this observation was not compensated by plasma refreshment, suggesting that some evidence of PSL may not be recovered after transfusion.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"391-403"},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-07-01 Epub Date: 2024-06-18 DOI: 10.1080/17474086.2024.2370092

引用次数: 0